Scilex Holding (SCLX) Other Non Operating Income (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Other Non Operating Income of -$279000.0 for Q1 2026, down 102.68% year-over-year from $10.4 million in Q1 2025, and down 100.34% on a QoQ basis from $82.1 million in Q4 2025.
Scilex Holding (SCLX) Other Non Operating Income (2021 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Other Non Operating Income for 6 consecutive years, with -$279000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 102.68% year-over-year to -$279000.0; the TTM figure through Mar 2026 stood at $81.7 million (up 222.33% YoY), while the FY2025 annual figure was $21.8 million, up 25.45% from the prior year.
- Other Non Operating Income came in at -$279000.0 for Q1 2026 at Scilex Holding, down from $82.1 million in the prior quarter.
- The five-year high for Other Non Operating Income was $82.1 million in Q4 2025, with the low at -$5.3 million in Q1 2023.
- Average Other Non Operating Income over 5 years is $6.7 million, with a median of -$2000.0 recorded in 2025.
- Across the five-year window, Other Non Operating Income sank 4047.37% in 2022 and soared 13593.55% in 2023, its largest moves.
- Year by year, Other Non Operating Income stood at $3.0 million in 2022, then tumbled by 67.71% to $972000.0 in 2023, then jumped by 1444.34% to $15.0 million in 2024, then surged by 447.09% to $82.1 million in 2025, then plunged by 100.34% to -$279000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$279000.0, $82.1 million, and -$2000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -279,000.00 |
| Dec 31, 2025 | 82.12 Mn |
| Sep 30, 2025 | -2,000.00 |
| Jun 30, 2025 | -99,000.00 |
| Mar 31, 2025 | 10.40 Mn |
| Dec 31, 2024 | 15.01 Mn |
| Sep 30, 2024 | -46,000.00 |
| Jun 30, 2024 | -5,000.00 |
| Mar 31, 2024 | -457,000.00 |
| Dec 31, 2023 | 972,000.00 |
| Sep 30, 2023 | 4.25 Mn |
| Jun 30, 2023 | -82,000.00 |
| Mar 31, 2023 | -5.25 Mn |
| Dec 31, 2022 | 3.01 Mn |
| Sep 30, 2022 | 31,000.00 |
| Jun 30, 2022 | -2.70 Mn |
| Mar 31, 2022 | 7.50 Mn |
| Dec 31, 2021 | -9.86 Mn |
| Sep 30, 2021 | 1.16 Mn |
| Jun 30, 2021 | 68,400.00 |